Ozempic vs Zepbound: One Is Approved for Weight Loss. One Isn't.

Ozempic or Zepbound: which should you ask for?

Start with the line that sounds like you:

• You have type 2 diabetes: Ozempic is the on-label choice. With commercial insurance, the savings card can bring it to $25.
• Your goal is weight loss and you have insurance with an obesity benefit: Zepbound is the drug approved for that use. Its savings card can bring it to $25.
• You pay cash for weight loss: Zepbound from Lilly, about $300 to $450 a month, is the approved option. The Ozempic pill costs less, about $150 to $300, but it is used off-label for weight.
• You're on Medicare: Part D can cover Ozempic for type 2 diabetes. For weight, the GLP-1 Bridge charges $50 for the Zepbound KwikPen if you qualify. Ozempic is not part of it.
• You have type 2 diabetes, no insurance and a low income: Novo Nordisk's assistance program may give you the Ozempic pen free.
• Your labs sit in the gray zone: ask a clinician which label your chart honestly supports, since neither card approves a mismatch.

Are Ozempic and Zepbound the same kind of drug?

No. Ozempic is semaglutide, made by Novo Nordisk. The FDA approved it on December 5, 2017, for adults with type 2 diabetes. Its highest dose is 2 mg. It has never been approved for weight management, so using it for weight loss is off-label.

Zepbound is tirzepatide, made by Eli Lilly, a different molecule. It acts on GLP-1 and on a second gut hormone, GIP. It was approved in November 2023 for weight management. In December 2024 it added moderate to severe sleep apnea in adults with obesity. Its doses run from 2.5 mg to 15 mg.

If you want semaglutide approved for weight loss, that is Wegovy, not Ozempic. Ozempic vs. Wegovy covers that. Zepbound's twin brand for diabetes is Mounjaro, covered in Mounjaro vs. Zepbound.

Is Zepbound more effective for weight loss than Ozempic?

Zepbound has a weight-loss trial behind it. Ozempic does not. In SURMOUNT-1, adults with obesity on 15 mg of Zepbound lost about 21% of their weight over 72 weeks, against about 3% on placebo.

Ozempic was never tested for weight loss on its own. The closest data come from SUSTAIN FORTE, a 40-week trial in people with type 2 diabetes. It compared 2 mg with 1 mg and had no placebo group. People on 2 mg lost about 6.4 kg, roughly 14 pounds, as a secondary result.

Those numbers are not a fair fight. The trials, people, goals and lengths all differ, and no trial has put Ozempic against Zepbound. The fair takeaway is narrower: Zepbound has direct evidence for weight loss, and Ozempic does not. For the molecule-level debate, see semaglutide vs. tirzepatide.

Ozempic vs Zepbound cost: what will each one cost you?

With insurance that matches the label, both can cost as little as $25 a month. Without it, the answer depends on the dose.

• Starting out: new Ozempic pen patients pay about $200 for their first two fills through Dec 31, 2026. Zepbound starts at about $300 at 2.5 mg.
• Ongoing: the Ozempic pen costs about $350 up to 1 mg and about $500 at 2 mg. Zepbound costs about $400 at 5 mg and about $450 from 7.5 mg, if you refill within 45 days.
• Late Zepbound refills: about $500 at 7.5 mg and about $700 from 10 mg.
• The Ozempic pill: about $150 to $300 a month, cheaper than Zepbound at every step. It is a diabetes drug, used off-label for weight.
• List price, no program: about $1,000 a month for Ozempic and about $1,085 for the Zepbound single-dose pen.

Lilly's self-pay prices and the Zepbound card run through Dec 31, 2026. NovoCare says its prices update after that date too. Ozempic cost and Zepbound cost cover every price path.

One gap favors Ozempic. Novo Nordisk's Patient Assistance Program gives the Ozempic pen free to some people with type 2 diabetes and no insurance. Household income must be at or below 200% of the federal poverty level. People with a Medicare drug plan no longer qualify. Lilly has no free program for Zepbound, and Lilly Cares lists only Trulicity, an older diabetes shot.

For the fine print on each program, see Ozempic savings, Ozempic without insurance, Zepbound savings and Zepbound without insurance. Ozempic cheapest and Zepbound cheapest rank every price we track.

Why would a doctor prescribe Ozempic instead of Zepbound?

It happens for practical reasons. Ozempic has been on the market six years longer, so many prescribers know it well. Some employer plans exclude every weight-loss drug but cover diabetes drugs, which can make Ozempic the only one a plan will pay for.

Cost matters too: the Ozempic pill starts at about $150 a month. Know one limit, though. Ozempic's savings card and assistance program require a type 2 diabetes prescription. An off-label prescription for weight loss doesn't qualify.

Which one does insurance or Medicare cover?

Commercial coverage follows the diagnosis on your chart. Type 2 diabetes makes Ozempic a normal claim for most plans. Obesity, or overweight with a condition like high blood pressure or sleep apnea, does the same for Zepbound, though obesity coverage varies a lot by employer.

Medicare Part D can cover Ozempic as a diabetes drug, at the plan's copay. In 2026, Part D drug costs stop at $2,100 a year.

For weight, the Medicare GLP-1 Bridge runs from July 1, 2026 to December 31, 2027. Eligible Part D members pay $50 a month for the Zepbound KwikPen, Wegovy or Foundayo. It excludes people with type 2 diabetes and does not include Ozempic, which has no weight-loss approval.

Are the side effects different?

They are the same kind. Both slow digestion, so nausea, vomiting, diarrhea and constipation are the most common, mostly in the weeks after a dose increase.

You can't rank them from their labels, because each label's numbers come from different trials. Ozempic side effects and Zepbound side effects cover each drug's full list.

Can you switch from Ozempic to Zepbound, or back?

Yes, but it is a real change of medicine. There is no established dose conversion between semaglutide and tirzepatide. Prescribers usually start Zepbound at 2.5 mg and climb again.

Common reasons are a plateau on Ozempic, a plan that starts covering Zepbound for weight, or a new obesity diagnosis that opens Zepbound's programs. For what a switch does to your bill, see Ozempic vs tirzepatide cost.

Does either make more sense in perimenopause or menopause?

Neither has been studied only in perimenopausal women. Falling estrogen is linked to more insulin resistance and more belly fat, and both drugs act on appetite and blood sugar.

The bigger issue is often paperwork. A rising A1C below the diabetes line, or weight gain below Zepbound's BMI rules, fits neither label. Zepbound's rules are a BMI of 30, or 27 with a weight-related condition. In that gray zone, a clinician who looks at hormones and metabolism together can help.